reason report
strong fear pbm biz model overblown sharehold vote
bottom line increas convict deep
valu invest solid beat rais quarter despit paus
buy-back showcas strong fundament across board
ep beat consensu revenu metric includ
cf solid global supplement busi perform
remark top-lin growth margin expans group
steadi ep guidanc rais continu
show impress growth commerci mid-market select
segment differenti self-insur plu stop loss offer
expect membership growth acceler cross-sel
financi flexibl medic cost moder offer
integr esrx mp product deal meaning accret
well guid admin cost synergi mm
excess see fear pbm margin compress
regulatori chang overblown even unlik event
drug rebat manufactur complet elimin
captiv pbm model add valu medic cost moder
align busi model end payor fear also
subsid given challeng logist entrench competit
hospit drug suppli chain link rais ep
back quarter remain consensu
expect sharehold vote come week posit
act catalyst expect stock trade deal break
strong driven global healthcar global
supplement global healthcar perform strongli
improv membership growth solid cash flow global
supplement also enjoy meaning top-lin growth growth
polici across china jv korea hong kong turkey margin
expans global disabl life held exhibit
healthcar metric solid consolid commerci
govern mlr improv beat consensu cfo ni
dcp day exhibit
ep guidanc rais ep guidanc rais
new rang revenu growth guidanc
year maintain medic membership growth guidanc
rais rang previou rang
 govern segment guidanc improv bp
commerci segment maintain exhibit
net debt total capit
price-to-earnings lt ep growth
ep
estimate lt ep growth compound-annual-growth-rate
compani inform leerink partner llc research
revenu billion quarterli number may add total due round
ep exclud item non-gaap ep quarterli number may add total due round
pleas refer page analyst certif import disclosur price chart disclosur specif
cover compani statement valuat risk avail
membership growth commerci middl market select
segment continu outperform peer ci maintain
differenti self-insur stop loss offer grew
teen rate select low singl digit mid-market
peer see membership declin move aso like
return hipf exhibit
cross-sel offer acceler growth across
combin ci esrx entiti given financi flexibl
afford deal ci ceo offer posit feedback deal
employ broker commun financi flexibl offer
accret esrx deal ci esrx
overlap mid-market fertil ground cross-sel exhibit
fear regul pbm margin compress overblown
view even drug manufacturer-bas rebat regul away
fear expect profit pool see meaning declin given
employ enjoy largest percentag rebat exhibit
much less overhang given decis
enter hospit drug suppli chain link logist control
substanc refriger cold chain deliveri kept
enter expect entri retail market also slow
link ci esrx state willing partner
rais ep estim remain consensu
rais ep estim ep estim
vs consensu exhibit
valuat compel view sharehold vote
pois posit catalyst ci trade attract
price-to-earnings stand-alon consensu ep combin
two compani estim manag estim
expect stock go either deal break deal close
sharehold vote serv posit catalyst exhibit
increas convict deep valu invest solid beat
rais quarter despit paus buy-back showcas strong fundament across
ep beat consensu revenu metric includ cf
solid global supplement busi perform remark top-lin growth margin
expans group steadi ep guidanc rais
continu show impress growth commerci mid-market select segment
differenti self-insur plu stop loss offer expect membership growth
acceler cross-sel financi flexibl medic cost moder offer
integr esrx product
deal meaning accret well guid admin cost synergi mm
excess see fear pbm margin compress regulatori
chang overblown even unlik event drug rebat manufactur
complet elimin captiv pbm model add valu medic cost moder
align busi model end payor
fear also subsid given challeng logist entrench competit
hospit drug suppli chain link
rais ep back quarter remain
consensu expect sharehold vote come week posit act
catalyst expect stock trade deal break close
strong ep beat driven global healthcar global supplement global
healthcar perform strongli improv membership growth solid
cash flow global supplement also enjoy meaning top-lin growth growth polici
across china jv korea hong kong turkey margin expans global disabl life
held
healthcar metric solid consolid commerci govern mlr improv
beat consensu cfo ni dcp day
ci report strong beat ep estim
ci earningsreport estimatesstreetaccount consensusreport sequentialreport yoytot net incom loss operationsglob disabl supplement incom loss oper per shareglob disabl supplement order invest corpor
metric sg solid estim
dcp flat yoy day
ci metricsreport estimatesstreetaccount consensusreport sequentialreport yoykey metricscommerci bpsgovern bpsconsolid bpstotal oper expens bpsday claim claim payabl corpor
ep guidanc rais new rang revenu growth
guidanc year maintain medic membership growth guidanc
rais rang previou rang govern segment
guidanc improv bp commerci segment maintain
compani rais ep guidanc mid-point new rang
membership growth commerci middl market select segment continu
outperform peer ci maintain differenti self-insur stop loss offer
grew teen rate select low singl digit mid-market peer
see membership declin move aso like return hipf
ci guidanceguid estimatesconsensu estimatesconsolid revenueyoy revenu medic membership growth medic medic health total oper expens health earn disabl life earn supplement benefit adj net incom guidanc exclud share corpor
histor ci seen growth middl market select segment
growth continu
cross-sel offer acceler growth across combin ci esrx entiti
given financi flexibl afford deal ci ceo offer posit feedback
deal employ broker commun financi flexibl offer accret
esrx deal ci esrx overlap mid-market fertil ground
cross-sel offer addit growth opportun ci esrx combin
revenu growth rollforwardstatu quo pro forma growth growth relat core plaform includ medicar advantag part growth relat express script enchanc reach expans term revenu increment growth opportun ci-esrx combin express script employ custom overlap approxim substanti cross-sel opportun product servic area express script also servic health plan govern entiti health servic capabl program expand area current oper well-perform senior busi highli reliant pharmaci servic express script lead capabl drive lower drug cost popul oper competit target go deeper geographi leverag express script stand-alon servic capabl abl quickli expand compet outsid go deeper geographi greenfield opportun exist key geographi neither express script signific health plan relationshipsbi leverag express script pharmaci manag servic abl deepli drive value-bas model healthcar provid pharmaceut manufactur therebi creat addit valu custom corpor
compani receiv posit feedback employ broker commun esrx deal
fear regul pbm margin compress overblown view even drug
manufacturer-bas rebat regul away fear expect profit pool see
meaning declin given employ enjoy largest percentag rebat
dialogu client well broker signific interact post announc macro favor reaction favor reaction expans capabl improv afford expans servic flexibl offer posit may recal talk addit uptick revenu standpoint new franchis abl deliv beyond base case organ identifi abil uptick within legaci relat addit growth opportun addit prior question indic modest amount overlap relationship exist today david cordani presid ceo director cigna corp con call cigna corpor
thesi around discount rebat esrx claim pass rebat receiv
esrx margin profil better competitor differenti line busi
much less overhang given decis enter hospit drug
suppli chain logist control substanc refriger cold chain deliveri kept
enter expect entri retail market also slow ci
esrx state willing partner
whole notion rel earn profil sustain earn spend moment clear strong margin profil rel tradit competitor unlik tradit competitor benchmark script focus pharmaci space exclus line busi kind cross margin otherwis addit market better understand disclosur taken place on-going dialogu portfolio busi littl differ broad commerci portfolio commerci portfolio larg nation account smaller nation account therefor margin profil littl differ standpoint secondli broad servic portfolio offer marketplac correl facilit prescript fulfil yet revenu earn henc make margin profil per script look bit higher david cordani presid ceo director cigna corp con call cigna corpor
much less overhang given decis enter hospit drug suppli chain
rais ep estim ep estim
vs consensu
rais ep ep
parent cash end net debt cap combin
two compani estim manag estim
ci strong capit posit parent ci-esrx combin expect
gener
incom non bp free cash flow end first quarter parent compani cash billion consid sourc use parent compani cash continu expect capit avail deploy billion forward project combin compani gener free cash flow least billion eric palmer cfo execut vice presid corp call corpor
net debt capit end
valuat compel view sharehold vote pois
ci trade attract price-to-earnings stand-alon consensu ep
expect stock go either deal break deal close sharehold vote
serv posit catalyst
ci trade price-to-earnings price-to-earnings stand-alon consensu ep
cigna inc ci incom mail order pharmaci invest invest gain expenseshealth care medic claim benefit order pharmaci cost good acquisit oper expens exclud special benefit continu oper incom tax net growth cigna corpor
health enrol access/oth guarante guarante legaci servic great west medic membership medic membership gw corpor
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
multipl expans use absolut rel price-to-earnings multipl base approach valuat
ep estim combin price-to-earnings base approach dcf model point
intrins valu compani plu add premium deal probabl
price target repres price-to-earnings ep
downsid risk invest thesi valuat aet legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn
upsid risk invest thesi valuat aet accret acquisit
aggress share repurchas use solid parent cash posit debt rais
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
new pt contempl price-to-earnings ep
risk invest thesi valuat
legisl regulatori polici chang could either dis-intermedi
insur us benefit marketplac place unforeseen top-lin margin
headwind commerci medicar advantag medicaid dual elig book
not-for-profit health insur price irrat commerci health benefit
acceler employ exit sponsorship health benefit us
marketplac post implement afford act
advers select public exchang protect adequ given delay
true-up govern payment
acquisit asset without attract return capit investor
organiz and/or oper risk drive execut mis-step downsid risk
earn
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform dcf valuat
leverag forward forecast wacc termin growth rate inform
potenti multipl expans along sector compani specif catalyst expect
greater potenti multipl expans dcf valuat point significantli upsid
peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans
base price-to-earnings multipl appli stand-alone ep rate ci
outperform price target
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti econom downturn
provid re-up intens servic deliveri cobra acceler uptak
member util care advanc layoff pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz econom downturn
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus
longer term state-bas insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress potenti downsid membership
polit shock lead singl payer
compani specif risk signific declin equiti market could result increas fund
compani pension oblig polit legal oper regulatori econom
risk foreign oper
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level free cash flow yield ratio also inform
potenti multipl expans except low ratio and/or high free cash flow yield
point potenti greater multipl expans price base case
ep estim
risk valuat includ
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid entitl program
state feder suprem court level also risk consid
remain posit reiter op rate month pt
contempl price-to-earnings ep
risk invest thesi valuat legisl regulatori
polici chang could either dis-intermedi health insur us benefit
marketplac place unforeseen top-lin margin headwind commerci medicar
advantag medicaid dual elig book busi not-for-profit health insur
price irrat commerci health benefit marketplac acceler employ exit
sponsorship health benefit us marketplac post implement
afford act advers select public exchang protect adequ
given delay true-up govern payment acquisit asset
without attract return capit investor organiz and/or oper risk
lead execut mis-step downsid risk earn acceler medic cost
trend util improv economi
pt reflect price-to-earnings ep
start-up cost underwrit issu associ new busi on-board
particularli challeng new popul dual elig
annual off-cycl rate chang state medicaid program
uncertainti associ competit bid process state
legisl regulatori judici polici chang medicaid
scale issu result loss specialti rx pharmaci contract
acquisit offer adequ return capit
upsid takeout substanti premium key risk
carve-out behavior health servic current state contract
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
base post month turnaround rate outperform pt
contempl price-to-earnings ep
risk highlight first spike util on-board new state contract
dual elig integr second state-bas insur exchang result advers
select reduc sustain earn power third state-bas contract rate increas
suffici cover medic trend off-set industri fee medicaid premium fourth risk re-
procur exist contract could creat substanti downsid risk volatil fifth
legisl judici risk manag medicaid entitl extrem case singl
payer model also possibl downsid
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free cash flow yield ratio also inform potenti multipl expans
except low ratio and/or high free cash flow yield point potenti greater
rate outperform price target contempl price-to-earnings
cash ep
non-profit bcb plan insur price irrat commerci market rapidli
medic cost trend come higher anticip potenti double-dip recess
provid re-up intens servic deliveri cobra acceler uptak member util
care advanc lay-off pandem
employ exit rapidli sponsorship health benefit combat medic cost
inflat catalyz double-dip recess
risk declin invest yield invest impair
state-bas actuari rate review limit sound price underwrit caus substanti
long-term state base health insur exchang advers select reduc
sustain earn power employ dump employe health insur
exchang signific margin compress also potenti downsid membership
risk relat collect industri fee medicar medicaid premium
polit shock lead singl payer
compani specif risk downsid risk price target includ acquisit asset
arena yield adequ return capit
primari valuat methodolog base rel price-to-earnings rel price-to-earnings
track function compani histori manag group averag assess
potenti price-to-earnings expans next month base forward forecast
contempl underli fundament implic healthcar reform
dcf valuat leverag forward forecast wacc termin growth rate
inform potenti multipl expans along sector compani specif catalyst
expect greater potenti multipl expans dcf valuat point significantli
upsid peer current trade level
free yield ratio also inform potenti multipl expans
except low ratio and/or high free yield point potenti greater
base rate wcg outperform pt contempl price-to-earnings
ep
downsid risk price target includ execut new state contract dual elig
award rate increas suffici cover medic trend state clawback tax off-set tax
reform tailwind potenti dial medicaid expans ky upsid risk price
target includ take-out larger player
